CCS
ARIA

Crosspoint Capital Strategies’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Crosspoint Capital Strategies’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5,000
Closed -$34K – 969
2015
Q4 		$34K Buy
+5,000
New +$32.8K 0.01% 501

Other funds holding ARIA

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Crosspoint Capital Strategies's ARIA Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2016, closing a stake of 5,000 shares — an estimated $34K sold.

Crosspoint Capital Strategies first reported a position in ARIA in Q4 2015 and held it in 1 quarter. The position peaked at $34K in Q4 2015. 162 funds tracked by Wall St. Rank hold ARIA as of Q1 2016.

  • Crosspoint Capital Strategies reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2016 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 5,000 Ariad Pharmaceuticals Inc shares in Q1 2016, an estimated $34K.
  • Crosspoint Capital Strategies first reported a position in Ariad Pharmaceuticals Inc in Q4 2015 and held it in 1 quarter.
  • Crosspoint Capital Strategies's Ariad Pharmaceuticals Inc position peaked at $34K in Q4 2015.
  • 162 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.